HCPLive Network

Despite Combined Antiretroviral Treatment, Anal Cancer Risk Still High for HIV-Infected

 
THURSDAY, Dec. 13 (HealthDay News) -- For HIV-infected patients, despite combined antiretroviral treatment (cART), the risk of anal cancer is still much higher than in the general population, according to a study published in the Dec. 10 issue of the Journal of Clinical Oncology.

Christophe Piketty, M.D., Ph.D., from the Hôpital Européen Georges Pompidou in Paris, and colleagues compared the incidence rates of anal cancer across four time periods: 1992 to 1996 (pre-cART); 1997 to 2000 (early cART); and 2001 to 2004 and 2005 to 2008 (both recent cART). During these periods, 263 cases of histologically confirmed invasive anal squamous cell carcinoma were identified.

The researchers found that, for HIV-infected patients, the hazard ratio for anal cancer was 2.5 in the cART periods versus the pre-cART period, with no difference noted across the cART calendar periods. In 2005 to 2008, compared with the general population, for HIV-infected patients there was an excess risk of anal cancer with a standardized incidence ratio of 109.8 for men who have sex with men (MSM), 49.2 for other men, and 13.1 for women. For patients with CD4 counts above 500/µL for at least two years, the standardized incidence ratios were 67.5 and 24.5, respectively, when the CD4 nadir was less than 200/µL for more than two years or more than 200/µL.

"Relative to that in the general population, the risk of anal cancer in HIV-infected patients is still extremely high, even in patients with high current CD4 cell counts," the authors write. "cART appears to have no preventive effect on anal cancer, particularly in MSM."
 

Abstract
Full Text (subscription or payment may be required)

 
Copyright © 2012 HealthDay. All rights reserved.
 

Further Reading
As the practice of telecare continues to gain momentum, a group of researchers conducted a study to test how effective that course of treatment is in patients with chronic illnesses.
Among couples with an HIV-positive member, a study in the Cochrane Database of Systematic Reviews (CDSR) deemed antiretroviral therapy (ART) effective at preventing HIV transmission to the HIV-negative partner.
Analysis of fatal cases of anaphylaxis in Canada uncovers several trends that point to a need for more effective monitoring and treatment strategies in high-risk patients.
GlaxoSmithKline's Arnuity approved for patients over the age of 12 as part of treatment options
Although ribotype 027 remains a significant cause of C. difficile infection (CDI), other strain types are gaining in prevalence, according to a study published in Antimicrobial Agents and Chemotherapy
Surgeons transplanted a kidney from a donor who had hepatitis C to a recipient who also has the disease in what is believed to be the first of its kind in the state of Utah.
Using the metric of time to first cigarette after waking (TTFC) was found to help improve efficiency and reduce false-positive detection in lung cancer screening, a new case-control study suggests.
More Reading